4.7 Article

Reality CHEK: Understanding the biology and clinical potential of CHK1

Journal

CANCER LETTERS
Volume 497, Issue -, Pages 202-211

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.09.016

Keywords

CHK1; Cell cycle; DNA Damage response

Categories

Funding

  1. Department of Defense [W81XWH1810054]
  2. U.S. Department of Defense (DOD) [W81XWH1810054] Funding Source: U.S. Department of Defense (DOD)

Ask authors/readers for more resources

The DNA damage response relies on CHK1 kinase for maintaining genomic integrity, involving in processes such as DNA replication and mitotic progression. While CHK1 has potential in cancer therapy, it has yet to be fully realized clinically.
The DNA damage response enables cells to cope with various stresses that threaten genomic integrity. A critical component of this response is the serine/threonine kinase CHK1 which is encoded by the CHEK1 gene. Originally identified as a regulator of the G2/M checkpoint, CHK1 has since been shown to play important roles in DNA replication, mitotic progression, DNA repair, and overall cell cycle regulation. However, the potential of CHK1 as a cancer therapy has not been realized clinically. Herein we expound our current understanding of the principal roles of CHK1 and highlight different avenues for CHK1 targeting in cancer therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available